Market news

FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceCompany to Present and Host 1x1 Investor Meetings on Tuesd...

39% Revenue Increase and 47% Growth in U.S. ProceduresFocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribut

FocalTherics™ Announces Proposed Public Offering of American Depositary SharesAUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- ...

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Na...

The latest analyst update on EDAP TMS centers on a revised fair value price target, moving from US$6.83 to US$8.50. That shift is tied to how analysts view high intensity focused ultrasound in prostate cancer, alongside potential upside from areas like benign prostatic hyperplasia and endometriosis that are often treated as optionality rather than fully reflected in core models. Read on to see what is driving this evolving narrative and how you can track it over time. Analyst Price Targets...